Published by mark itwired
Posted on September 22, 2021
Research firm Future Market Insights’ recent coverage on viscosupplementation market for the assessment period 2020-2030 concludes that a revenue share of US$ 4 Bn will be attained by 2030-end.
Rising incidence of osteoarthritis is pinpointed as the primary determinant for the expansion of the viscosupplementation market. According to the National Center for Biotechnology Information, osteoarthritis affects nearly 30% of the total population in the United States alone, while 10 to 15% of the global population suffers from the disease. Eight out of ten people experience severe restrictions in mobility due to the extreme pain they experience while a quarter of them find it difficult to perform daily chores.
In the light of such alarming increase in the number of cases, the demand for non-surgical methods to treat the ailment is providing traction to viscosupplementation procedures. The market growth is also being driven by enhancements in clinical efficacies of hyaluronic acid-based therapies, as majority of the patients suffer from knee osteoarthritis. These injections provide considerable relief from the pain by reducing joint inflammation.
Market players are increasingly advancing their R&D development capabilities to develop an additional pipeline of anti-osteoarthritis drugs imbued with hyaluronic acid for expanding their foothold. However, the coronavirus outbreak has impeded short-term growth prospects as patients are delaying treatments in favor of providing more room for the eradication of the pandemic.
For more insights into the Market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-9509
“Prominent players in the viscosupplementation market are emphasizing on developing cross-linked hyaluronic acid to provide immediate pain relief. Exhaustive investments are being undertaken by vendors to ensure that they acquire a competitive edge over their rivals,” infers an FMI analyst.
Prominent players in the viscosupplementation market have been profiled according to their geographical presence. For instance, the American viscosupplementation market is dominated by players such as Bioventus LLC, Anika Therapeutics Inc., Mylan N.V., OrthogenRx Inc. and Zimmer Biomet Holdings Inc. In Europe, the players are Ferring B.V, Sanofi S.A and Fidia Farmaceutici S.p.A while the Asia Pacific market consists of Chugai Pharmaceutical Co. Ltd and Seikagaku Corporation.
The aforementioned market players emphasize on innovative product formulations in order to expand their geographical presence across the continents. An example of this is CINGAL, the first and only approved combination viscosupplement which provides swift steroid action to effectively treat osteoarthritis symptoms. The injection provides relief for a long time period, typically for six months.
Also, OrthogenRx Inc. manufactures the TriVisc formulation which is a highly purified hyaluronic acid produced by bacterial bio fermentation. A major advantage of this product is that it mitigates risks of allergies and sensitivities and is safe for repeat injection cycles. Additionally, it is formulated by a fully automated manufacturing process which minimizes contamination and human error.
For information on the research approach used in the report, request methodology@ https://www.futuremarketinsights.com/askus/rep-gb-9509
The post Viscosupplementation Market 2021 | Present Scenario and Growth Prospects 2030 first appeared on Market Research Blog.
Research firm Future Market Insights’ recent coverage on viscosupplementation market for the assessment period 2020-2030 concludes that a revenue share of US$ 4 Bn will be attained by 2030-end.
Rising incidence of osteoarthritis is pinpointed as the primary determinant for the expansion of the viscosupplementation market. According to the National Center for Biotechnology Information, osteoarthritis affects nearly 30% of the total population in the United States alone, while 10 to 15% of the global population suffers from the disease. Eight out of ten people experience severe restrictions in mobility due to the extreme pain they experience while a quarter of them find it difficult to perform daily chores.
In the light of such alarming increase in the number of cases, the demand for non-surgical methods to treat the ailment is providing traction to viscosupplementation procedures. The market growth is also being driven by enhancements in clinical efficacies of hyaluronic acid-based therapies, as majority of the patients suffer from knee osteoarthritis. These injections provide considerable relief from the pain by reducing joint inflammation.
Market players are increasingly advancing their R&D development capabilities to develop an additional pipeline of anti-osteoarthritis drugs imbued with hyaluronic acid for expanding their foothold. However, the coronavirus outbreak has impeded short-term growth prospects as patients are delaying treatments in favor of providing more room for the eradication of the pandemic.
For more insights into the Market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-9509
“Prominent players in the viscosupplementation market are emphasizing on developing cross-linked hyaluronic acid to provide immediate pain relief. Exhaustive investments are being undertaken by vendors to ensure that they acquire a competitive edge over their rivals,” infers an FMI analyst.
Prominent players in the viscosupplementation market have been profiled according to their geographical presence. For instance, the American viscosupplementation market is dominated by players such as Bioventus LLC, Anika Therapeutics Inc., Mylan N.V., OrthogenRx Inc. and Zimmer Biomet Holdings Inc. In Europe, the players are Ferring B.V, Sanofi S.A and Fidia Farmaceutici S.p.A while the Asia Pacific market consists of Chugai Pharmaceutical Co. Ltd and Seikagaku Corporation.
The aforementioned market players emphasize on innovative product formulations in order to expand their geographical presence across the continents. An example of this is CINGAL, the first and only approved combination viscosupplement which provides swift steroid action to effectively treat osteoarthritis symptoms. The injection provides relief for a long time period, typically for six months.
Also, OrthogenRx Inc. manufactures the TriVisc formulation which is a highly purified hyaluronic acid produced by bacterial bio fermentation. A major advantage of this product is that it mitigates risks of allergies and sensitivities and is safe for repeat injection cycles. Additionally, it is formulated by a fully automated manufacturing process which minimizes contamination and human error.
For information on the research approach used in the report, request methodology@ https://www.futuremarketinsights.com/askus/rep-gb-9509
The post Viscosupplementation Market 2021 | Present Scenario and Growth Prospects 2030 first appeared on Market Research Blog.
Explore more articles in the Research Reports category
